Vivek Subbiah: Who said only movies come in trilogy?

Vivek Subbiah shared a post on LinkedIn:

“Who said only movies come in trilogy? Presenting the Precision Medicine Trilogy Series!
One of the main challenges in precision oncology implementation is navigating side effects & managing clinical adverse events in the real world.

Since we were intricately involved from the 1st patients in the world enrolled in clinical trials for BRAF, FGFR, & RET, we bring you. Clinical Development & Management of Adverse Events associated with FGFR BRAF, and RET inhibitors

Published open access for your reading in 3 different high impact CELL press journals for your Friday Reading  Sarah Cannon Research Institute, The US Oncology Network
BRAF
FGFR
RET

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the  Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.